Predictive value of MGMT promoter methylation status in Asian and Caucasian patients with malignant gliomas: a meta-analysis

about

Predictive value of MGMT promoter methylation status in Asian and Caucasian patients with malignant gliomas: a meta-analysis

Item

http://www.wikidata.org/entity/Q35679476

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Predictive value of MGMT promo ...... gnant gliomas: a meta-analysis

@ast

Predictive value of MGMT promo ...... gnant gliomas: a meta-analysis

@en

type

Item

label

Predictive value of MGMT promo ...... gnant gliomas: a meta-analysis

@ast

Predictive value of MGMT promo ...... gnant gliomas: a meta-analysis

@en

prefLabel

Predictive value of MGMT promo ...... gnant gliomas: a meta-analysis

@ast

Predictive value of MGMT promo ...... gnant gliomas: a meta-analysis

@en

P1476

Predictive value of MGMT promo ...... gnant gliomas: a meta-analysis

@en

P2093

Chao Chen

http://www.w3.org/2001/XMLSchema#string

Feng Wang

http://www.w3.org/2001/XMLSchema#string

Haiqing Huai

http://www.w3.org/2001/XMLSchema#string

Xueying Ren

http://www.w3.org/2001/XMLSchema#string

Yin Cheng

http://www.w3.org/2001/XMLSchema#string

Yuan Cheng

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.

Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma.

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

P304

6553-6562

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26131285

http://www.w3.org/2001/XMLSchema#string

P932

4483831

http://www.w3.org/2001/XMLSchema#string